Common Contracts
4 similar null contracts by Acorda Therapeutics Inc, Bottomline Technologies Inc /De/, Nevro Corp, TimkenSteel Corp
Nevro Corp.Nevro Corp • June 13th, 2016 • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $150,000,000 principal amount of its 1.75% Convertible Senior Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriters solely to cover over-allotments, up to an additional $22,500,000 principal amount of its 1.75% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such Option Securities granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock at the Company’
TIMKENSTEEL CORPORATION Underwriting AgreementTimkenSteel Corp • May 31st, 2016 • Steel works, blast furnaces & rolling mills (coke ovens) • New York
TimkenSteel Corporation, an Ohio corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $75,000,000 principal amount of its 6.00% Convertible Senior Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $11,250,000 principal amount of its 6.00% Convertible Senior Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 6.00% Convertible Senior Notes due 2021 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, common shares (the “Underlying Securities”) of the Company, without par value (the “Common Shares”), or a combination thereof, at the Company’s election, subje
ACORDA THERAPEUTICS, INC.Acorda Therapeutics Inc • June 23rd, 2014 • Biological products, (no disgnostic substances) • New York
Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”) $300,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriter, up to an additional $45,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriter shall have determined to exercise the option to purchase such 1.75% Convertible Notes due 2021 granted to the Underwriter in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock (any shares of Common Stock issuable upon conversion of the Securities, including, for the avoidance of doubt, any additional shares deliverable upon conv
BOTTOMLINE TECHNOLOGIES (de), INC.Bottomline Technologies Inc /De/ • December 13th, 2012 • Services-prepackaged software • New York
Bottomline Technologies (de), Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $165,000,000 principal amount of its 1.50% Convertible Senior Notes due 2017 (the “Underwritten Securities”) and, at the option of the Underwriters, up to an additional $24,750,000 principal amount of its 1.50% Convertible Senior Notes due 2017 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such 1.50% Convertible Senior Notes due 2017 granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash up to the aggregate principal amount of the Securities being converted and shares (the “Underlying Securities”) of common stock of the Company, p
